The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy

Approximately 90% of patients with the hematological malignancies termed the chronic myeloproliferative neoplasms harbor either the JAK2V617F-mutation or CALR exon 9 mutation. Both of these are recognized by T-cells, which make the mutations ideal targets for cancer immune therapy as they are shared...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncoimmunology
Hauptverfasser: Holmström, Morten Orebo, Hasselbalch, Hans Carl, Andersen, Mads Hald
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2017
Schlagworte:
Author's View
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5674967/
https://ncbi.nlm.nih.gov/pubmed/29147619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1358334
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge